

RECEIVED

NOV 28 2001

TECH CENTER 1600/2900

SEQUENCE LISTING

<110> Cooper, Denise R
Patel, Niketa A

<120> Introduction of a Glucose-Regulated Instability Element
Via Alternative Exon Inclusion of PKCBII mRNA in
Vascular Smooth Muscle Cells

<140> 114205-1200 Corrected

<140> 09/435,471

<141> 1999-11-08

<160> 14

<170> PatentIn Ver. 2.1

<210> 1

<211> 7

<212> PRT

<213> Homo sapiens

<220>

<223> Xaa at amino acid residues 2-6 is any amino acid
residue.

<400> 1

Cys Xaa Xaa Xaa Xaa Xaa Arg
1 5

<210> 2

<211> 11

<212> PRT

<213> Homo sapiens

<220>

<223> Xaa at amino acid residue 1 is Ile or Val; Xaa at
amino acid residue 10 is Ser or Thr; Xaa at amino
acid residues 4 and 7 is any amino acid residue.

<400> 2

Xaa His Cys Xaa Ala Gly Xaa Gly Arg Xaa Gly
1 5 10

<210> 3

<211> 9
<212> PRT
<213> Homo sapiens

<220>
<223> Xaa at residue positions 3-4, and 6-7 is any amino acid residue; Xaa at amino acid residue 9 is Ser or Thr.

<400> 3
His Cys Xaa Xaa Gly Xaa Xaa Arg Xaa
1 5

<210> 4
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
oligonucleotide primer

<400> 4
cgtatatgcg gccgcgttgt gggcctgaag ggg

33

C1

<210> 5
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
oligonucleotide primer

<400> 5
gcattctagt cgacaagagt ttgtcagtgg gag

33

<210> 6
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
oligonucleotide primer

<400> 6
gcattcthtc cagtgaggag aa

22

<210> 7
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
oligonucleotide primer

<400> 7
aaccagcacg ttgcccagga g

21

<210> 8
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
oligonucleotide primer

C1

<400> 8
cgtatatgcg gccgcgttgt gggcctgaag ggg

33

<210> 9
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
oligonucleotide primer

<400> 9
gcattctagt cgacaagagt ttgtcagtgg gag

33

<210> 10
<211> 351
<212> DNA
<213> Human PKC Beta II

<400> 10
 ttttaaacca aaagcttttt gggcgaaacg ctgaaacttc gaccggtttt tcacccgcca 60
 tccaccagtc ctaacacctc cgaccaggaa gtcatacagga atattgacca atcagaattc 120
 gaaggatttc ctttggttaac tctgaatttt taaaaccgga agtcaagagc tagtagatct 180
 gtagacctcc gtccttcatt tctgtcattc aagctcacag ctatcatgag agacaagcga 240
 gacacctcca acttcgacaa aagttcacca ggcagcctgt ggaactgact cccactgaca 300
 aactctgtcg actagaatgc cctgaattct gcagatatcc atcacactgc g 351

<210> 11
 <211> 39
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> metabolite responsive instability element

<220>
 <223> Description of Artificial Sequence: nucleic acid
 construct

<400> 11
 taactctgaa tttttaaaac ccgaagtcaa gagctagta 39

C1

<210> 12
 <211> 300
 <212> RNA
 <213> Human PKC Beta II

<400> 12
 uuuuaaacca aaagcuuuuu gggcgaaacg cugaaacuuc gaccgguuuu ucacccgcca 60
 uccaccaguc cuaacaccuc cgaccaggaa gucaucagga auauugacca aucagaauuc 120
 gaaggauuuc cuuuguuaac ucugaauuuu uaaaaccgga agucaagagc uaguagaucu 180
 guagaccucc guccuucuu ucugucuuuc aagcucacag cuaucaugag agacaagcga 240
 gacaccucca acuucgacaa aaguucacca ggcagccugu ggaacugacu cccacugaca 300

<210> 13
 <211> 175
 <212> RNA
 <213> Human PKC Beta II

<400> 13
 uuuuaaacca aaagcuuuuu gggcgaaacg cugaaacuuc gaccgguuuu ucacccgcca 60
 uccaccaguc cuaacaccuc cgaccaggaa gucaucagga auauugacca aucagaauuc 120
 gaaggauuuc cuuuguuaac ucugaauuuu uaaaaccgga agucaagagc uagua 175

C1
(end)

<210> 14
<211> 137
<212> RNA
<213> Human PKC Beta II

<400> 14
uuuuuaacca aaagcuuuuu gggcgaaacg cugaaacuuc gaccgguuuu ucacccgcca 60
uccaccaguc cuaacaccuc cgaccaggaa gucaucagga auauugacca aucagaauuc 120
gaaggauuuc cuuuguu 137
